Product Information
VENLAFAXINE HCL ER 225 MG TAB is a generic product labeled by Edenbridge Pharmaceuticals LLC, priced at $0.4712 per EA under NDC 42799096301. Its NADAC has been published 165 times since Aug 9, 2023.
FDA first approved this application on Oct 31, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
225 mg/1
Manufacturer
Edenbridge Pharmaceuticals LLCNDC
42799096301
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209193FDA Approved
10/31/2019
TE Code
AB
On Market Since
3/15/2023
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 225 MG TAB has been published 165 times since Aug 9, 2023, and over the history we have for it it has declined 45.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4712 per EA |
|---|---|
| All-time high | $1.2074 (Jan 10, 2024) |
| All-time low | $0.4592 (Nov 20, 2024) |
| 52-week high | $0.6436 |
| 52-week low | $0.4614 |
| Median price | $0.6653 |
| Average price | $0.6562 |
| Largest weekly change | +43.9% (Oct 18, 2023) |
| Weeks tracked | 165 |
| Tracking since | Aug 9, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Edenbridge Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
venlafaxine hydrochloride, extended release market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 225 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 225 MG TAB, manufactured by Edenbridge Pharmaceuticals LLC, is $0.4712 per EA (NDC 42799096301), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 225 MG TAB changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 225 MG TAB has declined 45.6%. It has been tracked across 165 weekly CMS publications since Aug 9, 2023.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 225 MG TAB?
Since Aug 9, 2023, the NADAC for VENLAFAXINE HCL ER 225 MG TAB has ranged from a low of $0.4592 (Nov 20, 2024) to a high of $1.2074 (Jan 10, 2024), with a median of $0.6653 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 225 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL ER 225 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL ER 225 MG TAB?
VENLAFAXINE HCL ER 225 MG TAB (NDC 42799096301) is labeled by Edenbridge Pharmaceuticals LLC, and CMS classifies it as a generic product.